Completed PHASE2 INTERVENTIONAL 2-arm NCT01733121

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Sponsor: Neurocrine Biosciences

Conditions Tardive Dyskinesia

Interventions NBI-98854 Placebo

Updated 7 times since 2017 Last updated: Jul 11, 2017 Started: Dec 31, 2012 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Tardive Dyskinesia and is currently completed. Neurocrine Biosciences leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurocrine Biosciences

Data source: Neurocrine Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Beachwood, United States , Bedford, United States , Boca Raton, United States , Caguas, Puerto Rico , Chicago, United States , Conshohocken, United States , Costa Mesa, United States , DeSoto, United States , Englewood, United States and 11 more locations